• Explore /
  • Poster
  • / A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).

A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).

Abstract Poster

Authors

null

Changying Guo

Jiangxi Provincial Tumor Hospital, Nanchang, China;

Changying Guo , Shengjia Chen , Yongqiang Ye , Wei-Min Mao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Other

Clinical Trial Registration Number

NCT05252078

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS488)

DOI

10.1200/JCO.2023.41.4_suppl.TPS488

Abstract #

TPS488

Poster Bd #

P3

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).

First Author: Changying Guo

First Author: Xianhai Mao

First Author: Hailiang Zhang

First Author: Toshiharu Hirose